Moser S, et al. - The efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) for 12 weeks was investigated among patients with chronic hepatitis C virus (HCV) genotype (GT) 3 and compensated liver disease in a real-life cohort from Austria. A 94% sustained virological response 12 weeks after the end of therapy (SVR12) rate was found in this cohort of compensated HCV-GT3-infected patients due to the highly effective 12-week course of SOF/LDV+RBV, despite a very weak antiviral activity of ledipasvir against HCV-GT3 in vitro. Therefore, SOF/LDV+RBV appeared to be an effective alternative in patients with HCV-GT3 infection if pangenotypic NS5A inhibitors were not available or not reimbursed by insurances.